Economidou-Karaoglou A, Opsomer M, Lans M, Taper H S, Deckers C, Roberfroid M B
Toxicologic and Cancerologic Biochemistry Unit, Medical Faculty, University of Louvain, Brussels, Belgium.
Acta Oncol. 1990;29(2):163-6. doi: 10.3109/02841869009126538.
The aim of this study was to evaluate the variation in serum alkaline DNase activity (SADA) as a means of therapeutic monitoring in patients with head and neck cancer. Blood samples from 40 patients were collected before, during, and some weeks up to months after therapy. A decrease in SADA during treatment was usually associated with a primary clinical response, while no decrease indicated non-response to therapy. In patients with complete tumor regression the initial decrease of SADA was usually followed by an increase exceeding the initial level. A similar increase was not observed in patients with tumor progression.
本研究的目的是评估血清碱性脱氧核糖核酸酶活性（SADA）的变化，以此作为头颈癌患者治疗监测的一种手段。在治疗前、治疗期间以及治疗后数周直至数月，收集了40例患者的血样。治疗期间SADA降低通常与初步临床反应相关，而未降低则表明对治疗无反应。在肿瘤完全消退的患者中，SADA最初降低后通常会出现升高且超过初始水平。在肿瘤进展的患者中未观察到类似的升高。
